Shots:

• Celgene acquires Juno- in all stock transaction with its JCAR017& JCARH125 clinical products. Juno to receive $87/share in cash- making total deal value as $9B
• The focus of the agreement is to develop drugs in fields of oncology and hematology with Juno’s cellular immunotherapy platform and research capabilities
• JCAR017 (lisocabtagene maraleucel; liso-cel) is a CD19-directed CAR T therapy- targeted for r/r diffuse large B-cell lymphoma (DLBCL) with its expected approval in 2019 by the US FDA. JCARH125 is an anti BCMA (B-cell maturation antigen) therapy- evaluated in P-I/II for r/r Multiple Myeloma
   

Ref: Celgene| Image: The Street